SCHEDULE: Alyeska Investment Group Discloses 7.53% Stake in INOVIO

Alyeska Investment Group, L.P. and its affiliates have reported a beneficial ownership of 7.53% in INOVIO PHARMACEUTICALS, comprising 4,000,000 shares through warrants.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have jointly reported beneficial ownership of 4,000,000 shares of INOVIO PHARMACEUTICALS Class A Common Stock.
• This ownership represents 7.53% of the company's outstanding Class A Common Stock.
• The reported shares are comprised of 2,000,000 Series A warrants and 2,000,000 Series B warrants.
• The percentage calculation is based on 53,571,675 outstanding Common Stock, as stated in INOVIO's Prospectus filed on November 6, 2025.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a prominent investment group like Alyeska is generally viewed positively as it indicates institutional confidence and potential long-term interest in the company. While it doesn't reflect operational performance, it can be a positive signal to the market.

Positives

• A significant institutional investor, Alyeska Investment Group, has taken a substantial stake in INOVIO PHARMACEUTICALS, indicating potential confidence in the company's future.
• The acquisition of 4,000,000 shares through warrants suggests a strategic investment with potential for future equity conversion.

Future Outlook

NA

Industry Context

The disclosure of a significant stake by an investment group like Alyeska in a pharmaceutical company such as INOVIO can signal increased institutional interest in the biotechnology or pharmaceutical sector, particularly in companies with specific pipeline developments or market positions. This could reflect broader trends in investor confidence in certain therapeutic areas or technological platforms within the industry.

Stakeholder Impact

• Shareholders: Existing shareholders may view the entry of a significant institutional investor positively, potentially leading to increased confidence and demand for the stock.
• Management: The presence of a large institutional holder may lead to increased scrutiny or engagement from the investor regarding corporate strategy and performance.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant institutional investment in INOVIO PHARMACEUTICALS by Alyeska Investment Group. While the acquisition of a 7.53% stake, primarily through warrants, suggests confidence from a sophisticated investor, the filing itself does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It's a factual disclosure of ownership. Investors should 'hold' and monitor for further developments, including the company's financial results and strategic updates, to assess the implications of this institutional interest. The warrants suggest a future potential for conversion, which could impact share structure.

Keywords

INOVIO PHARMACEUTICALS, Alyeska Investment Group, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, biotechnology, pharmaceuticals